All In Biotech

Drug Trial Radar · NCT04196257

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 19, 2022

Primary completion

Jul 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Bio-Path Holdings, Inc.Industry
Sponsor type
Industry
First posted
Dec 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.

Conditions

  • Solid Tumor, Adult
  • Carcinoma, Ovarian Epithelial
  • Fallopian Tube Neoplasms
  • Endometrial Cancer
  • Peritoneal Cancer
  • Solid Tumor

Interventions

  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)Drug

    Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.

  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxelDrug

    Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Identify Dose Limiting Toxicity (DLT) of BP1001-ATime frame: 30 days
  2. Identify maximum tolerated dose (MTD) of BP1001-ATime frame: 30 days
  3. Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-ATime frame: 30 days
  4. Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxelTime frame: 30 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Holy Cross Hospital

    Silver Spring, Maryland · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.